Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
apomine · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| apomine | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced or metastatic solid tumors refractory to standard therapy or for which no standard therapy exists (surgery, radiotherapy, and/or chemotherapy) Measurable or evaluable disease by medical photograph, plain x-ray, CT, M...
Apomine is an investigational small molecule being studied for the treatment of unspecified adult solid tumors, as defined by the specific protocols of its clinical trials. It is in Phase 1 clinical development for this oncology indication.
Apomine is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker symbol SNY.
Apomine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, with no active trials currently ongoing.
Apomine has been studied in two completed Phase 1 clinical trials: NCT00003822, which enrolled 30 patients with advanced solid tumors, and NCT00004049, which enrolled 36 patients with locally advanced or metastatic solid tumors. Both trials were conducted in the United States.
Yes, apomine is also known as SR-45023A. In its clinical trials, the drug was referred to by this alternative name, which may appear in related research publications or trial records.